Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 04 Oct 2024
Health news and commentary gathered by MedPage Today staff
Read Full NewsClinicians continue prescribing antibiotics unnecessarily despite growing evidence supporting shorter, targeted, and reassessed treatment strategies.
Nearly 300 experts warn that rising vaccine misinformation is reversing gains — measles and meningococcal infections are resurging while France updates the 2026 schedule.
Patients were randomly assigned 1:1 to receive either concurrent radiation dose escalation to the lumpectomy cavity during whole-breast irradiation or sequential boost after whole-breast irradiation.
The agency OK’d trastuzumab deruxtecan for two indications in HER2-positive early-stage breast cancer, covering both the neoadjuvant and adjuvant settings.
1.
CDC Alerts on Dramatic Rise in Human Parvovirus B19
2.
Obesity-related cancer rising among both younger and older adults worldwide, study finds
3.
According to JAMA, women who have false-positive mammogram results are at a higher risk of developing breast cancer over time.
4.
AI-based liquid biopsy shows promise for detecting brain cancer
5.
Only 1 in 4 Eligible Adults Receive Lung Screening
1.
Transforming Cancer Care: Metrics, Informatics, Equity, and Real-World Evidence
2.
Demystifying the Mentzer Index: Understanding Its Importance in Inventory Management
3.
Breakthroughs in Oncology: Advances in Immunotherapy, Radiation & Precision Diagnostics
4.
Discovering the Benefits of TNK: A Comprehensive Blog Article
5.
All You Need to Know About Mesna: The Ultimate Guide
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Updates on the First Line Management of ALK+ NSCLC
2.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part IV
3.
Navigating the Complexities of Ph Negative ALL - Part IV
4.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V
5.
What Therapy Would Yield the Best Outcomes In Patients with R/R B-cell ALL?
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge